GlaxoSmithKline Sells Equity Stake in ChemoCentryx to Vifor Pharma

October 23, 2018

Cleary Gottlieb represented GlaxoSmithKline in its all-cash sale of a 14.6 percent equity stake in ChemoCentryx to Vifor Pharma.

The transaction signed on September 17, 2018, and closed on October 23, 2018. The purchase price was approximately $86 million.

ChemoCentryx is a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer.